15 September 2026

ImmuPharma PLC
("ImmuPharma" or the "Company")

New peer-reviewed publication reports P140 activity in a preclinical MASH model

ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company, announces the publication of new peer-reviewed research evaluating P140 in a preclinical model of metabolic dysfunction-associated steatohepatitis ("MASH"). The paper, entitled "Restoring lysosomal proteostasis reverses steatohepatitis and fibrosis in experimental MASH", has been published in Pharmacological Research by researchers from CNRS and the University of Strasbourg, including Professor Sylviane Muller, co-inventor of P140.

Key findings

- P140 was evaluated in an established mouse model of advanced MASH characterised by liver inflammation and fibrosis.
- Treatment with P140 reduced steatohepatitis and fibrosis and improved several disease-related histological and biological parameters.
- P140 selectively modified a number of dysregulated lysosomal and autophagy-associated markers, while the scrambled control peptide did not reproduce these effects.
- The study provides further peer-reviewed evidence of the biological activity of P140 beyond its original lupus setting and supports continued investigation across diseases characterised by dysregulated cellular homeostasis and autophagy activity.

The study identified substantial disruption of lysosomal and autophagy-associated pathways in experimental MASH. P140 treatment was associated with selective changes in several abnormal markers and with reduced liver fibrosis and steatohepatitis.

The findings add to the growing body of peer-reviewed research around P140 and broaden understanding of its biological activity across different disease settings.

Professor Sylviane Muller, University of Strasbourg and CNRS, commented: "*These results provide important new evidence of the biological activity of P140 in an experimental model of advanced MASH. They further highlight the relationship between lysosomal and autophagy-associated pathways, inflammation and fibrosis, and support continued investigation of P140 across disease settings characterised by dysregulated cellular homeostasis.*"

Tim McCarthy, Chief Executive Officer of ImmuPharma PLC, commented: "*We congratulate Professor Muller and her collaborators on the publication of these important findings. The study adds valuable peer-reviewed evidence to the growing body of research around P140 and further demonstrates the breadth of its biological activity.*

We look forward to continuing our work with Professor Muller and our academic collaborators as we advance the development of P140."

The publication is available in Pharmacological Research, Volume 232 (2026), article 108427. doi: 10.1016/j.phrs.2026.108427

For further information please contact:

ImmuPharma PLC (www.immupharma.co.uk)	+44 (0) 207 206 2650
Tim McCarthy, Chief Executive Officer	
Lisa Baderoon, Head of Investor Relations	+ 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD)	+44 (0) 203 368 3550
Neil Baldwin	
Stanford Capital Partners (Joint Broker)	+44 (0) 20 3650 3650
Patrick Claridge, Bob Pountney	
SI Capital (Joint Broker)	+44 (0) 1483 413500
Nick Emerson	

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives.

For additional information about ImmuPharma please visit www.immupharma.co.uk.

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

About Reach announcements

Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages,

corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.